A biomarker for lymphangioleiomyomatosis

Affiliations

Comment

David Kwiatkowski. Lancet Respir Med. 2013 Aug.

. 2013 Aug;1(6):424-5.

doi: 10.1016/S2213-2600(13)70098-5. Epub 2013 Jun 20.

¹ Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Electronic address: dk@rics.bwh.harvard.edu.

No abstract available

Comment on

Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trial.
Young L, Lee HS, Inoue Y, Moss J, Singer LG, Strange C, Nakata K, Barker AF, Chapman JT, Brantly ML, Stocks JM, Brown KK, Lynch JP 3rd, Goldberg HJ, Downey GP, Swigris JJ, Taveira-DaSilva AM, Krischer JP, Trapnell BC, McCormack FX; MILES Trial Group. Young L, et al. Lancet Respir Med. 2013 Aug;1(6):445-52. doi: 10.1016/S2213-2600(13)70090-0. Lancet Respir Med. 2013. PMID: 24159565 Free PMC article. Clinical Trial.